Dosage, dosage and method of administration of icarelatumumab

Epcoritumab (Epcoritamab) is an immunotherapy drug for B-cell-associated lymphoma (non-Hodgkin lymphoma) . It uses a bispecific antibody mechanism to mobilize the patient's immune system to attack tumor cells by targeting CD3 and CD20. This drug uses different medication regimens when treating different types of lymphoma to ensure that the treatment is both safe and effective.

For patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma, the treatment regimen of icorelatumumab adopts a three-stage dose escalation strategy. In the first cycle, patients first received a dose of 0.16 mg on day 1, the dose was increased to 0.8 mg on day 8, the full dose of 48 mg was reached for the first time on day 15, and the dose of 48 mg was used again on day 22. Afterwards, in cycles 2 to 3, patients receive weekly injections of 48mg to ensure the drug continues to work in the body. After entering the 4th to 9th cycles, the frequency of treatment is adjusted to 48 mg injections every two weeks. Finally, starting from cycle 10, patients were treated with a monthly injection of 48 mg. Through this incremental dose and frequency adjustment, patients can gradually adapt to the drug and reduce the occurrence of side effects.

For patients with follicular lymphoma, treatment options are more gradual than for other types of lymphoma. In the first cycle, the dose started at 0.16 mg on day 1 and was gradually increased to 0.8 mg on day 8, 3 mg on day 15, and the full 48 mg dose on day 22. The treatment regimen for subsequent cycles is the same as for patients with other types of lymphoma, namely weekly injections of 48 mg from cycles 2 to 3, every two weeks from cycles 4 to 9, and finally monthly injections from cycle 10 onwards. All treatment cycles are 28 days, ensuring that patients receive continuous immune stimulation during the treatment process.

Icrituzumab is administered as a subcutaneous injection solution. Each treatment usually needs to be carried out in a hospital or medical institution by professional medical staff. Medication usage and dosage need to be individualized based on the patient's specific condition, tolerance to the medication, and physician's treatment plan. Patients need regular health monitoring while receiving treatment to ensure the medication is maximizing its effectiveness and minimizing potential side effects.

Reference materials:https://www.drugs.com/epcoritamab.html